Latest news with #AcuteCoronarySyndrome
Time of India
3 days ago
- Health
- Time of India
Heart health is a shared responsibility, says Novartis India head
A recent Beat Bad Cholesterol event by The Times of India group, in collaboration with Novartis, emphasized the need for the right kind of awareness, education and timely intervention in India where cardiovascular diseases are a leading cause of death. Cardiovascular diseases (CVDs) are the leading cause of death and disability in India. Calling it an 'epidemic' a 2023 study published in the medical journal The Lancet* says Indians have a higher relative risk burden of CVDs; an earlier age of onset; higher case fatality; and higher premature deaths. The World Health Organization (WHO) says that over 25% of deaths in India can be attributed to CVDs, and that they occur in an age group which is at least 10 years younger than that in the West. So, what is one to do in this situation? Recently, global pharma major Novartis and The Times of India hosted an event, titled Beat Bad Cholesterol, to spread the word about heart health and the dangers of LDL (low-density lipoprotein) cholesterol. Commonly known as the 'bad' cholesterol, LDL-C is a driver of CVDs, but it is also a modifiable risk. With the right kind of care and treatment, its risk as a primary cause of CVDs can be managed and even reduced. Novartis has a strong legacy of reimagining medicine for over 250 years and has partnered India's healthcare journey since 1947. For over 30 years it has been instrumental in transforming the standards of care for cardiovascular diseases, which is the world's primary cause of death, claiming nearly 18 million lives each year. Sadly, India accounts for one-fifth of these deaths caused by CVDs, worldwide. Elevated LDL-C is the main cause of Atherosclerotic Cardiovascular Disease (ASCVD), and is one of the neglected but important risk factors for CVDs. LDL-C is a critical cardiovascular disease marker to estimate the risk of Acute Coronary Syndrome (ACS), and several studies have shown that a reduction in LDL-C levels prevents cardiovascular outcomes. In a large, case-control INTERHEART study, it was found that among all the modifiable risk factors, abnormal lipid levels were identified to be associated with the highest population attributable risk (PAR 49.2%) for the occurrence of myocardial infarction. The most important risk factor identified across all geographic regions was LDL-C. In her inaugural address Ms Judith Love, President – APMA Region at Novartis, said: 'High LDL-C is a silent threat, often overlooked until it's too late. We believe that with the right awareness, regular screening, timely diagnosis and early treatment, we can change this trajectory. Initiatives like Beat Bad Cholesterol do more than raise awareness; they reinforce a collective commitment. It's encouraging to see a shared purpose across India's healthcare ecosystem, where every stakeholder has a vital role to play in advancing heart health. ' This was reiterated by Mr Rajeev D. Nivatkar, Commissioner of Medical Education and AYUSH. 'One of the most underestimated risk factors for heart attacks is bad cholesterol or LDL-C,' he said. 'It has no visible symptoms, yet it can quietly damage the heart and arteries over time. Many people are unaware of their numbers, and that has to change. We must encourage citizens to know their LDL-C numbers and consult their doctors proactively. ' Most stakeholders emphasised the need for regular lipid profile testing, since elevated levels of LDL-C (even when at dangerous levels) don't present any symptoms. In other words, one may not know about an increase in LDL-C levels until it's too late. The audience was also addressed by Mr Amitabh Dube, Country President and MD, Novartis India; Senior Cardiologist from Apollo Hospitals, Dr Nikhil Parchure; Mr Ram Khandelwal, Founder of Heart Health India Foundation, a patient advocacy group; and Mr Surinder Chawla, President & Head – Response, BCCL. Over 150 members of the audience -- including healthcare professionals, government officials and media leaders – also participated in a workout session conducted by celebrity fitness expert Aanchal Hans. According to Mr Amitabh Dube, 'Cardiovascular diseases continue to be a leading cause of mortality in India, and yet awareness of critical and modifiable risk factors like LDL-C remains low. Through Beat Bad Cholesterol, we aim to raise awareness and encourage people to 'know their LDL-C numbers' and work with their doctors to proactively manage their heart health. Novartis remains committed to advancing science and improving access to innovative therapies to help patients live longer, healthier lives. ' 'Reactions to LDL-C among patients is mixed,' says Mr Ram Khandelwal. 'Most know that they should not have high cholesterol, but only a few fully understand the dangers and the impact on one's heart. The urgency to act promptly to reduce high LDL-C is still missing. However, thanks to initiatives like Beat Bad Cholesterol, awareness is growing. People are getting sensitized and asking their doctors about target goals for LDL-C. In my understanding while engaging with heart patients, only five to 10% of them speak to their doctors about their target LDL-C.' Three key messages emerged from the event. First, that LDL-C is a modifiable, critical yet neglected cardiovascular risk factor. Second, most people only give importance to diabetes and hypertension, and neglect cholesterol management – even though 85% of all heart-related deaths are attributed to elevated LDL-C levels. Therefore, each one of us must talk to our doctor about our individual target LDL-C goals. Third, experts emphasise that heart treatment is not a one-size-fits-all option. As Ms Judith Love concluded: 'Each of us has a personal responsibility — not just to support these efforts, but to role-model healthy choices that protect our own hearts. India's scale, talent, and passion give us a powerful platform to drive lasting impact, and Novartis is proud to be part of this journey.' * One step to a healthier you—join Times Health+ Yoga and feel the change
Yahoo
23-04-2025
- Health
- Yahoo
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)
Roche, in collaboration with Universitätsklinikum Heidelberg, has developed a Chest Pain Triage algorithm – a CE-marked IVD medical device1 set to transform cardiac care This novel algorithm offers a standardised assessment, helping emergency room doctors to make confident clinical decisions in ruling in or ruling out heart attacks (acute myocardial infarction) Cardiovascular disease causes a third of worldwide deaths2, with chest pain being the second highest reason for emergency department (ED) visits3 Basel, 23 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of the navifyⓇ Algorithm Suite. This groundbreaking algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome (ACS) in patients presenting with chest pain, one of the most common reasons for Emergency Department (ED) visits. As EDs are typically one of the most crowded hospital units, leading to challenges to swiftly diagnose critical conditions, such as chest pain.4 This new algorithm was developed in collaboration with Universitätsklinikum Heidelberg. The Chest Pain Triage algorithm leverages state-of-the-art diagnostic technologies, including high-sensitivity cardiac troponin testing, to provide healthcare professionals with timely and reliable data to differentiate between cardiac and non-cardiac chest pain. This advanced algorithm is part of a wider integrated offering from Roche to address ACS, including the use of the cardiac troponin T Assay and integration with existing lab solutions, offering an efficient and comprehensive approach to patient triage in emergency settings. The Chest Pain Triage algorithm also leverages the European Society of Cardiology's (ESC) guidelines, and leading cardiologists and emergency medicine experts contributed to the development of the algorithm. "The introduction of our Chest Pain Triage algorithm underscores Roche's commitment to improving care for cardiovascular disease, one of the world's largest health burdens," said Matt Sause, CEO, Roche Diagnostics. "One of the major challenges in managing chest pain in the emergency department is the length of stay, especially since some patients aren't actually having a heart attack. Our Chest Pain Triage algorithm can help doctors quickly decide who needs urgent cardiac care and who could be discharged sooner. With an early rule-out pathway, we can cut down Emergency Department visit times by over three hours.5' The new algorithm aims to identify patients genuinely at risk by accurately identifying non-cardiac chest pain cases through a definitive Rule-In, Rule-Out or Observe recommendation according to the ESC guidelines. The algorithm simplifies decision making by automatically selecting the proper ESC 0/1, 0/2, or 0/3 accelerated pathway, based on the timing of the blood sample collection. This has the potential to reduce unnecessary hospital admissions and associated costs. The algorithm also expedites the treatment process for patients with true ACS with Rapid Assessments of chest pain onset more than three hours before the first blood sample. In addition, it includes a medical dossier for clinician support, and simplifies documentation by allowing doctors to easily copy recommendations and results into patient records. For more information, please visit the Chest Pain Triage algorithm site. The development of the Chest Pain Triage algorithm is part of Roche's commitment to early identification and treatment of Cardiovascular disease. The algorithm is available in Europe, the Middle East, and Asia, with availability in the United States at a later date, through Roche's navify Algorithm Suite, and can be integrated into current emergency department workflows*. Roche's cardiometabolic portfolio supports faster and more accurate triage decisions, and future ACS offerings will combine next-generation digital algorithms, biomarkers, near patient care devices, and laboratory analyzers. The navify Algorithm Suite is a cloud-based platform hosting clinical algorithms from Roche and partners. It provides labs and hospitals with direct workflow integration through Electronic Health Records (EHR) and Lab Information Systems (LIS) for faster and more efficient processes. About navify The navify portfolio from Roche includes more than 30 digital solutions for labs, hospitals and patients worldwide. navify solutions connect the healthcare community with a robust digital infrastructure to integrate data efficiently and to accelerate clinician access to innovations as well as operational and medical insights. This work includes collaborating with other innovative companies such as Fortinet in cybersecurity services. The navify platform is designed to deliver security at every step of the data analytical process. All data is encrypted at rest and in transit. The solution is operated in compliance with applicable laws and regulations in the USA with HIPAA (Health Insurance Portability and Accountability) as well as with GDPR (General Data Protection Regulation) regulations in Europe. Healthcare professionals can visit navify Marketplace to browse and request a growing number of next generation digital solutions from Roche and other companies — all designed to drive operational and clinical excellence, built on the foundational pillars of digital trust. More information is also available at About Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit All trademarks used or mentioned in this release are protected by law. * Availability will depend on the specific market and country in some cases. Please consult a local Roche representative for the availability of the chest pain algorithm in your market References [1] European Union: EUR-Lex. Chest Pain Triage algorithm registration [Internet: accesses March 24, 2025] Chest Pain Triage algorithm is an in-vitro diagnostic (IVD) medical device CE-marked (NB 0123) under the requirements laid out in the IVD regulation (EU) 2017/746 (IVDR). [2] Saloni D et al. Cardiovascular Diseases. [Internet: accessed March 24, 2025]. Available from: [3] Yukselen Z, Majmundar V, Dasari M, Arun Kumar P, Singh Y. Chest Pain Risk Stratification in the Emergency Department: Current Perspectives. Open Access Emerg Med. 2024 Feb 4;16:29-43. doi: 10.2147/OAEM.S419657. PMID: 38343728; PMCID: PMC10853047 [4] Sartini M, et al. Overcrowding in Emergency Department: Causes, consequences, and solutions – a narrative review. Healthcare (Basel). 2022 Aug;10(9):1625) [5] Anand A, et al. High-sensitivity cardiac troponin on presentation to rule out myocardial infarction: A stepped-wedge cluster randomized controlled trial. Circulation. 2021 Jun;143(23):2214-2224) Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Nina Mählitz Phone: +41 79 327 54 74 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Attachment 23042025_MR_Roche navify chest pain_en
